Report
Autolus R&D day outlines SLE data and path to market, MS up next
Yesterday, Autolus hosted an R&D day where it shared initial data from the phase 1 trial of obe-cel (CD19 CAR-T) in r/r SLE which showed that 3/6 patients achieved complete renal response (CRR). The company has aligned with the FDA on the route to market, and plans to initiate a pivotal phase 2 trial by YE25. In addition, Autolus announced its plan to evaluate obe-cel in progressive MS with a dose escalation trial due to begin by YE25. We reiterate our $ 10 TP and Buy rating.
Underlying
Autolus Therapeutics ADS
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.